|
|
Article: VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR.
- Article from:
- Worldwide Biotech
- Article date:
- August 1, 2004
CopyrightCOPYRIGHT 2004 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), Cambridge, Mass., and Mitsubishi Pharma Corporation have signed an agreement to develop and commercialize VX-950,
Vertex's investigational oral protease inhibitor for the treatment of hepatitis C virus (HCV) infection, in Japan and certain Far East countries.
As part of the agreement, Mitsubishi will make pre-commercial payments to
Vertex to support clinical development of VX-950. Additionally, Mitsubishi will pay royalties to Vertex on commercial sales of VX-950 in Mitsubishi's territories. Vertex will retain exclusive development and marketing rights to VX-950 in the rest of the world, ...